Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2004-11-30
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stria Gravidarum and Olive Oil for Pregnancy Women
NCT04489901
Comparison of 2 Body Oil in Prevention of Striae Gravidarum
NCT02879045
Consumption of Chocolate in Pregnant Women.
NCT01431443
In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers
NCT04431869
Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study
NCT05535660
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Women will be asked to apply a thin layer of the lotion to their abdomen, breasts and thighs once daily until the date of delivery. Participants will be recruited as early in their pregnancy as possible but will not be asked to start applying the lotion before 12 weeks of pregnancy. Women presenting after 20 weeks of pregnancy will not be eligible to participate in the study. The cocoa butter and placebo lotions have been made up to look, smell and feel the same and will be provided to the participants in identical containers. Women who have known hypersensitivity to cocoa butter or any of the components of the lotion will be excluded from the study.
Participants will be assessed at study entry for presence of stretch marks. Baseline information will be collected at that time including pre-pregnancy weight, skin type, and history of stretch marks in the mother or siblings. Women will then be followed up monthly by telephone to assess compliance with the regimen and ensure that they are not developing skin reactions.
Participants will be assessed for the development of stretch marks after delivery. Women will also be asked to provide their own assessment of their skin condition in terms of presence/absence of stretch marks and their severity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocoa butter application
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wellcome Trust
OTHER
American University of Beirut Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
American University of Beirut
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hibah Osman, MD
Role: PRINCIPAL_INVESTIGATOR
American University of Beirut Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
American University of Beirut
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Osman H, Usta IM, Rubeiz N, Abu-Rustum R, Charara I, Nassar AH. Cocoa butter lotion for prevention of striae gravidarum: a double-blind, randomised and placebo-controlled trial. BJOG. 2008 Aug;115(9):1138-42. doi: 10.1111/j.1471-0528.2008.01796.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R588416
Identifier Type: -
Identifier Source: secondary_id
FM.HO.01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.